The Ulcerative Colitis Game Of Thrones
Cory Renauer
•
Tue, May 21
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
26,314 people get JNJ articles and Market Currents by email alert.
Get email alerts on JNJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
The Ulcerative Colitis Game Of ThronesCory Renauer • Tue, May 21 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Johnson & Johnson's CEO Hosts Annual Meeting of Shareholders (Transcript)Thu, Apr 26, 2012 • 1 Comment
-
Johnson & Johnson Services, Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Johnson & Johnson Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Johnson & Johnson Q4 2009 Earnings Call TranscriptTue, Jan 26, 2010
-
Johnson & Johnson Q3 2009 Earnings Call TranscriptTue, Oct 13, 2009
-
Johnson & Johnson Q2 2009 Earnings Call TranscriptTue, Jul 14, 2009
-
Johnson & Johnson F1Q09 (Qtr End 03/29/09) Earnings Call TranscriptTue, Apr 14, 2009 • 1 Comment
-
Johnson & Johnson Q4 2008 Earnings Call TranscriptTue, Jan 20, 2009
-
at CNBC.com (Fri, 1:43PM)
-
at CNBC.com (Fri, 11:27AM)
-
at MarketWatch.com (Fri, 7:00AM)
-
at CNBC.com (May 14, 2013)
-
at MarketWatch.com (May 14, 2013)
-
at MarketWatch.com (May 12, 2013)
-
at MarketWatch.com (May 3, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
PR Newswire (Apr 25, 2013)
-
PR Newswire (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
JNJ vs. ETF Alternatives
Company Description
General
Johnson & Johnson and its subsidiaries have approximately 115,500 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 31, 4:09 PM Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII. Comment! [Healthcare, M&A]
- Thursday, January 31, 9:33 AM EU antitrust regulators send Johnson & Johnson (JNJ -0.1%) and Novartis (NVS -0.3%) a "statement of objections," or charge sheet, over a "co-promotion" deal they formulated that delayed the release of a generic competitor to J&J's painkiller fentanyl in Holland for 17 months in 2005-2006. The EU can levy fines of up to 10% of annual sales for anti-competitive behavior, although penalties are usually based on the revenues of the product involved. (PR) Comment! [Healthcare]
- Wednesday, January 30, 3:08 PM An orthopedic surgeon who helped design the all-metal hip implant that Johnson & Johnson (JNJ -0.4%) recalled in 2010 says the device wasn’t defective as he testified in the first of thousands of cases set to go to trial. “I have not used the term ‘defective’” the surgeon testified in a videotaped deposition. JNJ claims the implant was properly designed and the plaintiff's claim of elevated metal levels in his body can be traced to conditions including diabetes, high blood pressure and cholesterol, strokes and kidney cancer. 1 Comment [Healthcare]
- Friday, January 25, 6:30 PM In its effort to shed its non-core businesses Johnson & Johnson (JNJ) is reportedly shopping its women's health unit. The unit, which competes with products from Procter & Gamble (PG), had world-wide sales of around $1.6B in 2012, which represents just a small percentage of JNJ's $67B in total sales over the same period. Still, with the right price tag, it's big enough to potentially pique the interest of private-equity buyers. 3 Comments [Healthcare]
- Wednesday, January 23, 6:13 AM Johnson & Johnson (JNJ) knew that a metal hip-replacement implant was problematic in 2008, a year before the company halted production of the product and two years before recalling it, court documents show. The documents are part of a lawsuit whose opening arguments are due to start on Friday. Overall, J&J faces 10,000 suits over the implant, for which its estimated liability is over $1B. 2 Comments [Healthcare]
- Tuesday, January 22, 10:01 AM J&J (JNJ -0.5%) is exploring the options for its Ortho Clinical Diagnostics (OCD) unit, including a divestiture if "it is determined that OCD could have greater potential as part of another organization whose focus is more closely aligned with its core strengths, or by operating as a stand-alone company." Comment! [Healthcare, Top Stories]
- Tuesday, January 22, 8:18 AM More on J&J (JNJ -0.7%) Q4: expects 2013 EPS of $5.35-$5.45 vs consensus of $5.49. 2012 results boosted by upper respiratory over-the-counter products, international sales of Listerine, and U.S. sales of Neutrogena skin care products. Sales were hurt by generic competition for Levaquin and the manufacturing suspension at a third party supplier for Doxil. (PR) Comment! [Healthcare]
- Tuesday, January 22, 8:03 AM More on Johnson & Johnson (JNJ) Q4: net profit excluding special items +7.9% to $3.4B; those items amount to $800M, and include "litigation accrual" and program costs associated with DePuy's recalled artificial hip. Acquisition of Synthes contributes 5.6% to sales growth. Domestic revenues +6.8%, international +8.9%. Shares -0.9%. (PR) Comment! [Earnings, Healthcare]
- Tuesday, January 22, 7:47 AM Johnson & Johnson (JNJ): Q4 EPS of $1.19 beats by $0.02. Revenue of $17.6B (+8% Y/Y) misses by $0.07B. Shares -1.3% premarket. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Tuesday, January 22, 12:04 AM Notable earnings before Tuesday’s open: AMTD, CNI, CRBC, DAL, DD, EAT, FCX, FMER, JNJ, KSU, MTG, PETS, RF, SNV, TRV, VZ, WAT Comment! [Earnings]
- Friday, January 18, 2:56 PM Johnson & Johnson (JNJ) has reportedly offered to pay more than $200k per hip case, for a settlement that would top $2B. Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%) have been the subject of thousands of patient lawsuits for their metal-on-metal hip implants, which have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011. 3 Comments [Healthcare]
- Thursday, January 17, 7:44 PM The FDA is concerned whether several medical devices already on the market, such as electroconvulsive therapy devices for depression and emergency defibrillators, require additional evidence to prove they're safe. It's issued a safety advisory, saying patients with symptoms suggesting their devices aren't functioning properly should be considered for testing of possible metal ions in their bloodstream. Symptoms include: skin rashes, neurological changes such as hearing and vision impairment, and psychological status changes including depression. Comment! [Healthcare]
- Friday, January 11, 5:52 AM An FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's (JNJ) canagliflozin treatment for Type 2 diabetes, although several of the panelists expressed concerns about its cardiovascular risks and its use for patients with moderate kidney disease. If authorized, analysts have forecast that canagliflozin could generate annual sales of $667M by 2016. Comment! [Healthcare]
- Tuesday, January 8, 10:24 AM The FDA says Johnson & Johnson's (JNJ +0.1%) diabetes drug Invokana was effective at lowering a key measure of blood sugar, but the agency raised concerns about potential stroke and bone-related safety risks. The drug is due to be reviewed on Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The agency released its review of the product today in preparation for the panel meeting. Comment! [Healthcare]
- Monday, January 7, 4:33 AM Jury selection is due to begin today in the first trial over Johnson & Johnson's (JNJ) Gynecare Prolift vaginal mesh implant, which a South Dakota woman says has caused her constant pain and has led to 18 operations. The complaint is one of 1,800 against Prolift, which J&J has said it will stop selling, while other manufacturers of similar implants also face lawsuits. (previous) Comment! [Healthcare, Top Stories]
- Friday, January 4, 9:04 AM Johnson & Johnson (JNJ) is raised to Buy from Hold with an $82 price target, up from $75, at Deutsche Bank, which cites improving sales trends and benefits of diversification. Recent and new drugs should continue to drive pharma sales, and JNJ should continue to work through the McNeil Consent Decree and return consumer products to market. JNJ +0.6% premarket. 1 Comment [Healthcare, Quick Ideas]
-
- View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 0 replies
-
Dividend Sheet
$AZN $GSK $MRK are the best yielding heathcare stocks with a lower volatility than the market - http://stks.co/cP2U - $JNJ $TEVA - View all 0 replies
-
Jim Van Meerten
$JNJ - 100% Barchart technical buy signals - 16 new highs and up 6.49% in the last month - Relative Strength Index 80.62% - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Daniel Nadler
These 11 Dow Jones Stocks Have Now Returned More Than 10% in 2013: http://stks.co/eOvQ $DIA $SPY $HPQ $JNJ - View all 0 replies
-
Mesteve0319
$JNJ was the second stock I ever bought. After 8 years, I finally sold. It was a good run! - View all 0 replies
-
- View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
Dividend Sheet
$GE $JNJ $JPM and $AAPL are George Soro's Biggest Dividend Stocks Bets - http://stks.co/q5zi - 20 Shares with 0.93% average yield - View all 0 replies
LATEST REPLIES
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in THE TANER DATA (my Instablog) with their security names. yk
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in the Daily TANER Momentum [DTM] (my Instablog) with their security names. yk
-
- View all 3 replies
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly <c>
-
O. Young Kwon: The letters in the parentheses are ticker symbols which are in the Daily TANER Momentum [DTM] (my Instablog) with their security names. yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (9/20/2012, Thursday) Numbers = Term in months. The TANER Stock Model [TSM} was introduced in my <c>
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (9/18/2012, Tuesday) Numbers = Term in months. The TANER Stock Model [TSM} was introduced in my <c>
-
O. Young Kwon: article: Link:http://seekingalpha.com/a/hitr The TANER System synthesizes performances and relative strengths thoroughly yk
-
- View all 5 replies
-
-
O. Young Kwon: @ tashe. Thanks. Please make my number to a three digit, will you? Have a good summer. yk
-
- View all 3 replies
-
-
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/16/2012, Monday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: 2 = 2-month term. Momentum can help you (a) to manage your portfolios piecemeal, not on-off fashion,<c>
-
O. Young Kwon: and (b) to decide what securities (ETFs and Stocks) to buy, sell, or hold. yk
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/13/2012, Friday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/12/2012, Thursday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/11/2012, Wednesday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
- View all 2 replies
-
O. Young Kwon: SUMMARY OF STOCK TANER MOMENTUM (S.TM) (7/5/2012, Thursday) 1,2,3 = 1-m, 2-m, 3-month term. <c>
-
O. Young Kwon: The TANER System synthesizes performances and relative strengths of 20 ETFs and 40 equities thoroughly yk.
-
Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS - View all 1 replies
-
-
- View all 2 replies
-
O. Young Kwon: 3 = 3-m term. The TANER System captures dynamics of momentum changes of individual securities on the daily basis.<c>
-
O. Young Kwon: The System also builds successfully their momentum trends over time. yk